# Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

> **NCT03671733** · PHASE3 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 150 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Exenatide
- **DRUG:** Exenatide Microspheres for Injection

## Key facts

- **NCT ID:** NCT03671733
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671733, "Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03671733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*